ArticleFrontiers in pharmacology2026
Post-market safety profile and suicide risk signals of vortioxetine: a real-world pharmacovigilance study.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Vortioxetine inhibits 5-HT transporter-mediated 5-HT reuptake and simultaneously regulates the activities of various 5-HT receptors to exert an antidepressant effect. It has been proven to be a highly effective antidepressant that can significantly improve depressive symptoms. However, the real-world evidence of vortioxetine-associated suicidal signals is very limited. We explored the vortioxetine-related suicidal signals by mining the US FDA Adverse Event Reporting System (FAERS) database. Methods: This study used the disproportionality method to systematically evaluate the vortioxetine-related adverse events (AEs). Data were collected from the fourth quarter (Q4) of 2013 to the second quarter (Q2) of 2025 in the FAERS database. The report was analyzed by four signal detection methods, namely, reported odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and multi-item gamma Poisson shrinker (MGPS). The contingency table was analyzed to compare the proportion of suicide-related reports across different subgroups. Results: A total of 13,698 vortioxetine-related reports were cleaned from the FAERS database. From these reports, 27 system organ classes (SOCs) and 173 preferred terms (PTs) were identified. The top three SOCs were psychiatric disorders, general disorders and administration site conditions, and gastrointestinal disorders. Significant suicide-related signals were detected for suicidal ideation (ROR = 19.87), suicide attempt (ROR = 7.05), completed suicide (ROR = 4.73), suicidal behavior (ROR = 13.57), and suicide threat (ROR = 15.47). The contingency table analysis revealed that sex ( Conclusion: This study aligns with regulatory warnings and underscores the importance of clinical vigilance when prescribing vortioxetine. Enhanced monitoring is recommended for all patients, with particular attention given to younger populations during treatment initiation. Due to the inherent limitations of spontaneous reporting systems, these findings should be interpreted as hypothesis-generating signals requiring confirmation through controlled studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.